Wang 2007.

Methods	Allocation: randomised. Blindness: single. Duration: 72 hours.
Participants	Diagnosis: CCND‐3 diagnosis of schizophrenia with agitation/aggression. N = 32. Age: mean 25.8 (SD 10.4) years (haloperidol group), 28.6 (SD 9.4) years (ziprasidone group). Sex: 16 males and 16 females. History: first episode (N = 27), relapse (N = 5). Excluded: direct blood relatives of staff in current trial, participation in other drug trials 30 days prior to enrolment, pregnant or lactating women, severe disease/unstable medical condition, clinically significant abnormal EEG or laboratory results, QTC interval ≥ 450, family history of sudden death, drug abuse in past year, regular user of antipsychotic, antidepressant, depot medication, ziprasidone or haloperidol in past 30 days, people with drug‐induced malignant syndrome, suicidal ideation, or known allergy to ziprasidone or haloperidol. Setting: inpatient, China*.
Interventions	1. Haloperidol: flexible dose 5 mg/IM, to 10 mg/IM, repeated every 4‐6 hours if necessary, maximum dose 30 mg during 24 hours. N = 16. 2. Ziprasidone: flexible dose 10 mg/IM, to 20 mg/IM, repeated every 4‐6 hours if necessary, maximum dose 40 mg during 24 hours. N = 16.
Outcomes	Mental state: PANSS. Global State: CGI. Agitation: PANNS‐EC, ACES. Adverse effects: BAS.
Notes	*It is not clear if this paper presents the results from one centre of the Li 2006 multi‐centre trial. Attempted to contact author to clarify.